Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.40 | 15.50 | -0.18% |
| CAC 40 | 7,718.05 | 21.78 | 0.28% |
| DAX 40 | 24,032.49 | 245.04 | 1.03% |
| Dow JONES (US) | 44,547.02 | 281.51 | -0.63% |
| FTSE 100 | 8,811.35 | 11.56 | -0.13% |
| HKSE | 23,887.83 | 28.23 | -0.12% |
| NASDAQ | 20,454.48 | 146.62 | -0.71% |
| Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
| NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
| S&P 500 | 6,242.42 | 36.93 | -0.59% |
| S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
| SSE Composite Index | 3,473.13 | 0.81 | 0.02% |